Phenylephrine 2.5%, 10% · ophthalmic solution
Mydriatics/Cycloplegics
Approved uses
Mydriasis, age 1 year and older
1 drop of 2.5% or 10% every 3 to 5 minutes, maximum 3 drops per eye, repeated if necessary
Mydriasis, infants under 1 year
1 drop of 2.5% at 3 to 5 minute intervals, maximum 3 drops per eye
OFF-LABELNot in the FDA label for this product
Horner syndrome, denervation supersensitivity testing
1 drop of a 1% dilution in each eye, pupils measured 1 hour later in bright light; 1% is not a marketed strength and must be diluted
Observational · 71% sensitive
In a standardized series, 71% of sympathetically denervated or decentralized Horner pupils were supersensitive to 1%; a normal 20-year-old dilates by no more than 2.1 mm in bright light at 1 hour, sensitivity rises 0.23 mm per decade, and the interocular difference should not exceed 0.7 mm. The author concluded that supersensitivity is a useful but not invariable feature, so a negative test does not exclude the diagnosis.
Episcleritis versus scleritis, vasoconstriction test
Topical instillation over the injected sector, then re-examine those vessels for blanching; no standardized concentration, and 10% was the strength used in the single reported case
Review + case report
A vasculitis review states that episcleritis blanches on instillation of topical phenylephrine while scleritis is painful and does not blanch, without specifying a concentration; in a reported case of nodular anterior scleritis, hyperemia persisted after 10%. No study of diagnostic accuracy and no standardized concentration or reading time was found, so treat the result as supportive rather than definitive.
Contraindications
- Hypertension or thyrotoxicosis, for the 10% solution; the 2.5% solution should be used in these patients.
- Age less than 1 year, for the 10% solution, due to increased risk of systemic toxicity; the 2.5% solution should be used in these patients.
Ophthalmic solution, 2.5% (10 mL, 15 mL), 10% (5 mL fill in a 10 mL bottle)
Alpha-1 adrenergic receptor agonist that acts locally as a potent vasoconstrictor and mydriatic, constricting ophthalmic blood vessels and contracting the radial muscle of the iris. Maximal mydriasis occurs at 20 to 90 minutes with recovery after 3 to 8 hours, and systemic absorption of sufficient quantities may lead to a rise in blood pressure, which may be accompanied by a reflex atropine-sensitive bradycardia.
Warnings & Precautions
- Cardiovascular reactions: Serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, have been reported in patients using phenylephrine 10%; these episodes, some fatal, have usually occurred in patients with pre-existing cardiovascular diseases, and the 2.5% solution should be used in these patients.
- Elevation in blood pressure: A significant elevation in blood pressure is not common but has been reported after recommended doses of the 10% solution, and the risk is less with 2.5%; use caution with 10% in pediatric patients less than 5 years of age and in hyperthyroidism or cardiovascular disease, and carefully monitor post-treatment blood pressure in cardiac or endocrine disease and in any patients who develop symptoms.
- Rebound miosis: Reported one day after instillation, with a lesser mydriatic effect on re-instillation.
- Exaggerated pressor responses: Concomitant use of phenylephrine and atropine may enhance the pressor effects and induce tachycardia in some patients, and phenylephrine may potentiate the cardiovascular depressant effects of some inhalation anesthetic agents.
- Sympathomimetic cautions: A survey of systemic reactions to ophthalmic drug preparations found that both 2.5% and 10% phenylephrine have been associated with cardiovascular effects and should be used with caution in selected patients on monoamine oxidase inhibitors, tricyclic antidepressants or atropine or in those with hypertension, advanced arteriosclerotic changes, aneurysms, orthostatic hypotension, long-standing insulin-dependent diabetes and in children with low bodyweights.
- Overdosage: Overdosage of phenylephrine may cause a rapid rise in blood pressure, headache, anxiety, nausea, vomiting, and ventricular arrhythmias; prompt injection of a rapidly acting alpha-adrenergic blocking agent such as phentolamine has been recommended.
- Not for injection: Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is indicated for topical ophthalmic use and is not indicated for injection.
Common Side Effects
Eye pain and stinging on instillation, temporary blurred vision and photophobia, and conjunctival sensitization may occur. Cardiovascular reactions following topical ocular use of the 10% solution have occurred primarily in hypertensive patients and include marked increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia and subarachnoid hemorrhage. A marked increase in blood pressure has been reported particularly, but not limited to, low weight premature neonates, infants and hypertensive patients. These reactions are reported voluntarily from a population of uncertain size, so it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Pregnancy: Animal reproduction studies have not been conducted with the topical drug and fetal harm potential is unknown; give only if clearly needed.
Lactation: Excretion in human milk is unknown; exercise caution in a nursing woman.
The 10% solution is contraindicated under 1 year of age; use 2.5%.